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Interleukin-16 (IL-16) is reported to be a chemoattractant
cytokine and modulator of T-cell activation, and has been pro-
posed as a ligand for the co-receptor CD4. The secreted active
formof IL-16has beendetected at sites ofTH1-mediated inflam-
mation, such as those seen in autoimmune diseases, ischemic
reperfusion injury (IRI), and tissue transplant rejection. Neu-
tralization of IL-16 recruitment to its receptor, using an anti-
IL16 antibody, has been shown to significantly attenuate inflam-
mation and disease pathology in IRI, as well as in some
autoimmune diseases. The 14.1 antibody is a monoclonal anti-
IL-16 antibody, which when incubated with CD4 cells is
reported to cause a reduction in the TH1-type inflammatory
response. Secreted IL-16 contains a characteristic PDZ domain.
PDZ domains are typically characterized by a defined globular
structure, along with a peptide-binding site located in a groove
between the B and B structural elements and a highly con-
served carboxylate-binding loop. In contrast to other reported
PDZ domains, the solution structure previously reported for
IL-16 reveals a tryptophan residue obscuring the recognition
groove.We have solved the structure of the 14.1Fab fragment in
complex with IL-16, revealing that binding of the antibody
requires a conformational change in the IL-16 PDZ domain.
This involves the rotation of the B-helix, accompanied move-
ment of the peptide groove obscuring tryptophan residue, and
consequent opening up of the binding site for interaction. Our
study reveals a surprising mechanism of action for the antibody
and identifies new opportunities for the development of IL-16-
targeted therapeutics, including smallmolecules thatmimic the
interaction of the antibody.
Interleukin-16 (also known as lymphocyte chemoattractant
factor) was first described in 1982 as a T-cell chemoattractant
factor produced by antigen and mitogen-stimulated lympho-
cytes (1). An array of immune and non-immune cells are now
known to express IL-16 as one aspect of an inflammatory
response, including CD4 and CD8 T cells, eosinophils,
monocytes, mast cells, and dendritic cells (2–5). In addition,
IL-16 has been reported to promote the entry of resting CD4
T cells into the cell cycle, and the up-regulation of IL-2 receptor
and major histocompatibility (MHC) class II proteins on cell
surfaces (6, 7).
Human IL-16 (hIL-16)4 is expressed as a 631-amino acid pre-
cursor protein and contains three PDZ domains, along with an
N-terminal CcN motif, encompassing both CK2 and cdc2
kinase phosphorylation sites, a nuclear localization signal, and
an Src homology 3 binding motif (Fig. 1A) (8, 9). Following
cytosolic proteolysis of hIL-16 by caspase-3, a 121-amino acid
fragment encompassing the C-terminal PDZ domain (residues
527–619) is secreted as themature form of IL-16 (10). Secreted
IL-16 has been reported to bind to CD4 with relatively high
affinity (6, 11, 12), which is consistent with IL-16 functioning as
a pro-inflammatory cytokine. The protein is reported to have
two major effects on CD4 cells: chemoattraction, preferen-
tially of TH1 cells, and inhibition of CD3/T-cell mediated acti-
vation, preferentially of TH2 cells (13). Co-incubation of CD4
cells with an anti-CD4 antibody (OKT4) is reported to lead to a
reduction in the magnitude of IL-16-induced cell migration by
monocytes (11). The protein CD4 contains four immunoglob-
ulin (Ig)-like domains (D1–D4), and CD4-derived peptide inhi-
bition studies of IL-16-mediated chemotaxis suggested that
IL-16 binds toCD4D4 (6). There is also evidence to suggest that
chemokine receptor 5, which is expressed on the surface of TH1
cells, enhances the binding of IL-16 to the co-receptor (14).
Interestingly, the chemotactic activity of hIL-16 is not asso-
ciatedwith a characteristic chemokine structuralmotif (15, 16).
The solution structure of mature hIL-16 has been reported and
showed the chemokine to contain a classical PDZ domain, con-
sisting of a central up and down -sandwich, adjacent to an
-helix (17). PDZ domains typically assist in the assembly of
multiprotein signaling complexes, by binding peptides in a
groove between the1-helix and2-strand, in a process known
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as -strand addition (18). This peptide recognition is mediated
by a conserved GLGF motif termed the “carboxylate-binding
loop,” which coordinates a number of hydrogen bonds to the
C-terminal carboxylate of the binding peptide. Surprisingly, the
typical PDZ-peptide binding groove is blocked by an aromatic
side chain in the reported hIL-16 structure, despite conserva-
tion of the GLGF motif.
There is high sequence homology for IL-16 across mamma-
lian species, with over 85% sequence similarity between human
andmurine IL-16. The extent of the conservation is even higher
at the C-terminal peptide-binding interface associated with
typical PDZ activity (Fig. 1B), strongly suggesting a conserved
functional importance. However, the reported tight interaction
between IL-16 and CD4 (Kd  230 pM) has been proposed to
involve a cluster of residues close to the C terminus of IL-16
(616RRKS619) (14, 19) (Fig. 1B).
IL-16 is associated with disease pathogenesis in a number of
autoimmune conditions, with expression levels raised in serum
from patients with rheumatoid arthritis, multiple sclerosis, and
systemic lupus erythematosus (15, 20, 21). The incubation of
dendritic cells with a mouse anti-IL-16 monoclonal antibody
(mAb 14.1) was reported to result in a significant reduction in
cell migration in cultures of epidermal cells (22). Furthermore,
neutralization of hIL-16 by mAb 14.1 produced a reduction in
theTH1-type inflammatory response (2) and themAb14.1 anti-
body has shown in vivo efficacy in a rodent model of acute
kidney injury (23). The potential of hIL-16 as a therapeutic tar-
get in a range of autoimmune conditions has led to the devel-
opment of a panel of inhibitory monoclonal antibodies. In this
communicationwe report the structure of a promising Fab can-
didate (c14.1) based on mAb 14.1 bound to hIL-16, which
reveals an unexpected binding site for the inhibitory antibody
on the opposite face of the protein to the proposedCD4binding
site. In addition, the structure of the c14.1FabIL-16 complex
reveals a significant conformational change in hIL-16, allowing
residues from the CDR loops to make extensive contacts in the
generic PDZ domain peptide-binding groove. This raises the
possibility of the IL-16 PDZ domain modifying its activity via a
cryptic peptide binding site. The structural changes induced in
hIL-16 by the inhibitory antibody binding also reveal new
opportunities for the design of small molecule inhibitors to tar-
get hIL-16 activity.
Experimental Procedures
Expression and Purification of hIL-16—A recombinant pro-
tein corresponding to mature secreted human IL-16 (residues
502–631) with an N-terminal His6 tag was expressed as a solu-
ble product using a pLEICS-01 vector (Protex, University of
Leicester) transformed into the Escherichia coli strain BL21
(DE3) (Novagen). Uniformly 13C/15N/2D- and 15N-labeled
hIL-16 were prepared by growing at 37 °C in modified Spizizen
minimal medium (24, 25) containing 15NH4SO4 (4 g liter1)
and/or [13C6]glucose (2 g liter1) as required, with deuterated
samples grown in media dissolved in 100% D2O. The protein
was purified to homogeneity by chromatography on affinity
(nickel-nitrilotriacetic acid column, Qiagen) and gel filtration
FIGURE 1. IL-16 domain structure. A, IL-16 is expressed as a 631-amino acid precursor protein comprising an N-terminal CcNmotif and three C-terminal PDZ
domains. Caspase-3 cleaves the precursor protein at Asp510, between PDZ domains 2 and 3, releasing the mature secreted IL-16 component (2). B, multiple
sequence alignment of secreted mammalian IL-16 proteins, revealing high sequence homology in the 2 to 3 strand and 1-helix regions. The secondary
structure based on human IL-16 is shown above. With the exception of the3/4 loop region, the core of the protein has very high sequence homology across
all mammalian species. Putative CD4 binding site residues highlighted (). The figure was prepared using ESPript 3.0 (46).
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(Superdex 75 16/60, GEHealthcare) columns, into a final buffer
of 25 mM phosphate, pH 7.0, 100 mM NaCl, 100 M EDTA, 1
mM DTT, 2 mM MgCl2, and 1 mM imidazole. The His tag was
removed prior to gel filtration using tobacco etch virus protease
overnight at 4 °C.
Expression and Purification of Truncated hIL-16 (hIL-16tr)—
The DNA construct for the truncated form of human IL-16
(IL-16tr, residues 523–622) with an N-terminal His tag was
cloned into pLEICS-01 and transformed in E. coli BL21 cells.
The soluble protein was expressed in 2YTmedia at 18 °C and
purified to homogeneity by chromatography on affinity (nickel-
nitrilotriacetic acid column, Qiagen) and gel filtration (Super-
dex 75 16/60, GE Healthcare) columns, into a final buffer of 20
mMTris-HCl, pH 7.4, 50mMNaCl, and 1mMDTT. TheHis tag
was removed prior to gel filtration using tobacco etch virus
protease overnight at 4 °C.
Expression and Purification of the Anti-IL-16 c14.1Fab—The
variable domains from the heavy and light chains of the parent
murine anti-IL-16 antibody (14.1) were identified by sequence
analysis and subcloned into in-house pCMV-based vectors,
containing a C-terminal reading frame for either the first con-
stant domain of human IgG1 (CH1) or the human  constant
domain (CL), respectively. For expression of the c14.1Fab, the
two plasmids encoding the heavy and light chain fragments
were transiently co-transfected into Expi293FTM cells (Invitro-
gen) according to themanufacturer’s instructions. Cell cultures
were maintained for 7–10 days in Expi293TM medium at 37 °C
(130 rpm and8% CO2 in humidified air) before supernatants
were harvested by centrifugation, filter-sterilized (Stericup;
Merck Millipore), and stored at 4 °C until required. The
secreted c14.1Fab was purified by affinity chromatography,
with the harvested supernatant loaded onto a 1-ml KappaSelect
column (GEHealthcare) pre-equilibratedwith phosphate-buff-
ered saline, pH 7.4, (PBS) and the bound antibody was eluted
by 0.1 M glycine, pH 2.5–3.0. The final sample was desalted
and buffer exchanged into PBS using a PD10 column (GE
Healthcare).
Expression and Purification of Extracellular Regions of
Human CD4 (hCD4)—DNA inserts comprising hCD4 domains
D1–D4 (residues 1–388) and hCD4 D3D4 (residues 202–388)
were synthesized and cloned into pcDNA3 (Life Technologies).
The hCD4 D3D4 insert also incorporated an additional N-ter-
minal Ig leader sequence to facilitate protein secretion. Both
expression vectors also included aC-terminalHis6 tag to enable
affinity-based protein purification. For recombinant hCD4
expression, Expi293FTM cells (Life Technologies) were tran-
siently transfectedwith plasmidDNAaccording to themanufa-
cturer’s instructions and cell cultures (0.2 liter) were main-
tained for 7–8 days in Expi293TM medium at 37 °C (130 rpm
and8% CO2 in humidified air). Supernatants were harvested
by centrifugation, filter-sterilized (Stericup;MerckMillipore),
and subsequently stored at 4 °C. The two hCD4 extracellular
region proteins (D1–D4 and D3D4) were purified to homoge-
neity using a HisTrap-excel column (GE Healthcare) and by
size exclusion chromatography using either a Superdex 75 (16/
60; GE Healthcare) or Superdex 200 (26/60; GE Healthcare), as
appropriate, into a final buffer of PBS.
Complex Preparation—The c14.1FabIL-16 and c14.1FabIL-
16tr complexes were prepared by mixing the c14.1Fab with
either hIL-16 or hIL-16tr at a Fab:IL-16molar ratio of 1.2:1. The
mixtures were incubated for 60 min at 4 °C, concentrated with
a Vivaspin-20 to a final volume of 2.0 ml, and purified on a
Superdex 75 16/60 column (GE Healthcare). The running
buffer used was either 25mM phosphate, pH 7.0, 100mMNaCl,
100 M EDTA, 1 mM DTT, and 1 mM imidazole or 20 mM
Tris-HCl, pH 7.4, and 50 mM NaCl, for the c14.1FabIL-16 and
c14.1FabIL-16tr complexes, respectively. Fractions corre-
sponding to the protein complex peak in each case were pooled
and concentrated for NMR and crystallographic studies with a
Vivaspin-20. As expected, the complex formation in both cases
resulted in a significant shift in retention time on a Superdex 75
column compared with that for the free c14.1Fab and hIL-16.
NMR Spectroscopy—All NMR data were acquired on Bruker
Avance III 600 and 800 MHz spectrometers equipped with
5-mm HCN cryoprobes. Both the hIL-16 and c14.1FabhIL-16
NMR samples were prepared at 150M in 25mM sodium phos-
phate buffer, pH 7.0, containing 100mMNaCl, 100MEDTA, 1
mM DTT, and 1 mM imidazole in 90% H2O, 10% D2O. The
two-dimensional 15N-1H TROSY spectra of hIL-16 were
obtained at 25 and 35 °C, in the absence or presence of
c14.1Fab, respectively. Typical acquisition times for the triple
resonance experiments were 80ms in F3 (1H), 22ms in F2 (15N),
and 6 or 25 ms in F1 (13C) as appropriate, with the spectra
collected over13–60 h. All datasets were non-uniform sam-
pled to 25% and reconstructed using hmsIST software (26).
Backbone amide chemical shifts for free hIL-16were consistent
with those reported previously. However, all backbone assign-
ments were confirmed using three-dimensional HNCO,
CBCACONH, and CBCANH experiments, allowing for the full
assignment of peaks from the 15N-1HTROSY spectra. All NMR
data were processed and analyzed using NMRPipe (27)
and SPARKY (University of California, San Francisco, CA)
software.
The minimal shift approach (28) was used to identify hIL-16
residues involved in c14.1Fab binding. Backbone amide mini-
mal shift values were obtained from the combined chemical
shift change in 15N and 1H for each assigned peak in the 15N/1H
TROSY spectrum of the free 15N-labeled hIL-16, when com-
pared with all peaks observed in the 15N/1H TROSY spectrum
of the 15N-labeled hIL-16 bound to unlabeled c14.1Fab. A his-
togram of combined minimal shift versus protein sequence
revealed residues fromhIL-16with backbone amide signals sig-
nificantly perturbed by antibody binding.
Protein Crystallography—Initial crystallization trials for the
c14.1FabIL-16tr complex were performed at 20 mg/ml using
sitting drop vapor diffusion and 96-well block screens (Molec-
ular Dimensions) at 20 °C. Optimal crystals of c14.1FabhIL-
16tr grew in 16% PEG3350, 0.1 M Bistris propane, pH 6.5, and
0.2 M sodium sulfate. A cryoprotectant consisting of 22% (v/v)
ethylene glycol in mother liquor was used. X-ray diffraction
data were collected at the Diamond Light Source (Oxford, UK)
using beamline I03.
Diffraction data were indexed and integrated in Xds (29) and
scaled using SCALA (30). A Matthews coefficient (31) calcu-
lated one molecule of c14.1Fab and one molecule of hIL-16tr
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present in the asymmetric unit. A homology model of c14.1Fab
was generated using SWISSMODEL (32) with the deposited
antibody structures Protein Data Bank codes 4F33 (33) and
1I7Z (34), used to model the heavy and light chains, respec-
tively. The structure of the c14.1FabhIL-16tr complex was
determined by molecular replacement, using the program
PHASER (35), with the hIL-16 NMR structure (PDB code 1I16)
and the c14.1Fab homology model used in the search. Model
building and structural refinement was carried out with Coot
(36), PHENIX (37), and REFMAC 5.0 (38) using restrained
refinement and isotropic B-factors. X-ray data collection and
refinement statistics are given in Table 1.
ELISA-type c14.1mAb-IL-16 Binding Assays—Wells on
streptavidin HBC plates (Thermo Scientific) were coated over-
night at 4 °C with 50 l of 0.048–25 g/ml of recombinant
hIL-16 or hIL-16 W600A in Dulbecco’s PBS (Thermo Scien-
tific). After blocking with 2% BSA in PBS at room temperature
for 1 h, 50 l of 1 g/ml of c14.1 antibody in Dulbecco’s PBS
with 0.1% BSA was added to the wells and incubated for 1 h at
room temperature. Following incubationwithHRP-conjugated
anti-mouse (Fc specific) antibodies (Sigma A2304) (1:5,000
dilution) at room temperature for 1 h, the substrate 3,3,5,5-
tetramethylbenzidine (Sigma, T4444)was added and allowed to
develop. Bound proteins were quantified after measuring the
absorbance at 450–650 nm in a microtiter plate reader (Tecan
Saffire), and data were analyzed by GraphPad Prism software.
FlowCytometryAnalysis of OKT4Antibody and hIL-16Bind-
ing to Cell Surface CD4—Flow cytometry analysis of both
hIL-16 and OKT4 antibody binding to cell surface CD4 was
performed in duplicate, with 1  105 cells per well in FACS
buffer (PBS  2% FBS). The OKT4 antibody binds to the D3
domain of CD4. CD4ve cells were incubated with hIL-16 (3.3
ng/ml to 33 mg/ml) for 2 h at 4 °C, followed by biotinylated
OKT4 (eBioscience 13-0048) at 500 ng/ml final concentration
and streptavidin Alexa Fluor 488 (Invitrogen, S11223) at 2
g/ml final concentration for 30 min at 4 °C, then analyzed
using a Millipore guava easyCyte.
Results and Discussion
Mapping the Binding Site of the c14.1Fab on hIL-16—Resi-
dues from hIL-16 significantly perturbed by the interaction
with the c14.1Fab were identified by comparison of 15N/1H
TROSY spectra acquired for the free and antibody bound pro-
tein (Fig. 2). Comprehensive backbone and side chain assign-
ments have been previously reported for hIL-16 (17), and it
proved relatively straightforward to obtain nearly complete
backbone resonance assignments for free hIL-16 under our
experimental conditions. The observed minimal shifts in back-
bone amide signals of hIL-16 on complex formation are sum-
marized in the histogram shown in Fig. 2A and mapped onto
the structure of free hIL-16 to clearly identify a contiguous anti-
body interaction surface. c14.1Fab binding to hIL-16 results in
very significant shifts (N-H   0.15 ppm) for 15 residues
(Gly542, Gly544, Ser546, Gly549, Gly550, Ser553, Asp557, Thr561,
Arg564, Met591, Arg596, Trp600, Asn601, Ile603, and Ala605),
which form the interaction surface highlighted in Fig. 2B. These
residues are predominantly localized to the 2 and 3 strands,
the 2/3 loop, and the neighboring 1-helix, collectively
forming a continuous patch of683 Å2 on the surface of hIL-
16, which is consistent with the size expected for an antibody
binding site (39, 40). Surprisingly, the antibody interaction sur-
face identified does not include the residues previously
reported to be involved in binding to CD4 (Arg616, Arg617, and
Lys618), suggesting that the inhibitory activity of c14.1Fab is not
due to direct blocking of CD4 binding to hIL-16.
Structure of the c14.1FabhIL-16 Complex—To further char-
acterize the interaction of the c14.1Fab with hIL-16 and the
molecular basis of the inhibition of activity, the structure of the
c14.1FabhIL-16 complex was solved by x-ray crystallography
to 2.1 Å. The published solution structure of mature hIL-16
(PDB 1I16) revealed highly flexible regions on either end of the
central PDZ3 domain (17). In addition, the NMR interaction
studies reported here show that these regions are not involved
in c14.1Fab binding and that the PDZ3 domain alone contained
the entire antibody interaction site. Consequently, an isolated
PDZ3 domain hIL-16 construct was prepared corresponding to
residues 523–622 (hIL-16tr) and assessed for crystallographic
studies. Size exclusion chromatography confirmed that this
truncated form of hIL-16 (hIL-16tr) still boundwith high affin-
ity to the c14.1Fab molecule and crystals of the antibodyhIL-
16tr complex were obtained that diffracted to 2.1 Å.
Analysis of the diffraction data indicated that the crystals
contained one molecule of IL-16trc14.1Fab complex in the
asymmetric unit. Interpretable electron density was obtained
for hIL-16tr residues Glu527 to Ser619, c141.1Fab heavy chain
(VH) residues Glu1 to Ser223, and c14.1Fab light chain (VK) res-
idues Asp1 to Cys218. The c14.1Fab is a chimeric version of the
mouse derived 14.1 inhibitory anti-IL-16monoclonal antibody.
The sequences of the three complementarily determining
regions (CDR) in the light (L1, L2, L3) and heavy chains (H1,
H2, and H3) can be classified as L1 (Arg24-His38), L2 (Tyr53-
Ser60), L3 (Gln93-Thr101), H1 (Gly26-Asn35), H2 (Leu50-Asp66),
and H3 (Ser99-Tyr110), respectively (Chothia numbering sys-
TABLE 1
X-ray data and refinement statistics
c14.1Fab-hIL-16
Data collection
Wavelength (Å) 0.97626
Space group P212121
Cell dimensions
a, b, c (Å) 59.69, 65.95, 196.44
, , 	 (o) 90, 90, 90
Resolution (Å) 29.45–2.07
Rmerge 0.055 (0.695)
I/
I 17.79 (3.44)
Completeness (%) 99.81 (99.85)
Redundancy 6.3 (6.5)
Matthews coefficient 0.983
Solvent content (%) 63.86
Refinement
No. of reflections 304,909 (22954)
No. of unique reflections 48,100 (4710)
Rfactor/Rfree (%) 17.18 (20.53)
Wilson B-factors (Å) 39.24
B-factors (Å)
Protein 44.90
Solvent 53.50
Root mean square deviations
Bond lengths (Å) 0.008
Bond angles (°) 1.15
Ramachandran plot
Most favored (%) 96.3
Allowed (%) 3.5
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tem (41)). The structure of the protein complex shows hIL-16tr
bound to the conventional antigen binding surface on the
c14.1Fab (Fig. 3). The overall structure of the antibody-bound
hIL-16tr molecule is very similar to the published hIL-16 free
structure (C root mean square deviation  2.09 Å), with the
exception of residues 569–575, which appear to be disordered
in the crystal structure. The most notable difference in the
backbone was for Leu554 (10.2 Å in C positions), which is
situated in the 2/3 loop that was shown to be dynamic in
solution (17). In complex with the c14.1Fab the hIL-16 2/3
loop interactswithCDR-H1,which is likely to stabilize this loop
region of hIL-16 and may induce a change in conformation
compared with the free protein.
Features of the Antibody-IL-16 Interface—The c14.1Fab-IL-
16tr interface buries 876 Å2 of antibody protein surface from
bulk solvent, with 603 Å2 of the buried surface from the VH
domain and 273 Å2 from the VK domain. In the case of IL-16 a
comparable surface of 853 Å2 is buried by complex formation.
This is consistent with the contact surface area estimated from
the NMR studies discussed earlier and lies within the typical
range of 850 	 130 Å2 for an antibody-binding site on target
proteins (39, 40). With the exception of CDR-L3, at least one
residue from all CDR loops is within 5 Å of hIL-16, with 22
amino acids from the CDR loops losing at least 10 Å2 of solvent
accessibility and making direct contacts with hIL-16. The
extensive interface features amixture of polar and hydrophobic
contacts, including the involvement of eight aromatic side
chains in the CDR loops, from both the VH (Tyr52, Tyr74,
Tyr121, Tyr122, and Tyr127) and VK (Tyr59, Tyr61, and Tyr78)
domains. Of these, all are forming hydrogen bonds through
their side chain hydroxyl groups, with the exception of Tyr59,
Tyr61, and Tyr121. Examples of the interactions seen between
the antibody and hIL-16 are illustrated in Fig. 4.
There are 25 residues from hIL-16 within 5 Å of c14.1Fab in
the complex, which form a continuous contact surface com-
prising -strands 2 and 3, the 2/3 loop, and 1 helix (Fig.
3B). This antibody binding site on hIL-16 contains many of the
residues, which show substantial changes in the backbone
amide chemical shifts on complex formation (Fig. 2A and 2B),
including residues Gly542, Gly544, Ser546, Ser553, Arg564, Arg596,
Trp600, and Ile603. However, significant shifts in backbone
amide signals were also seen for several residues not directly
involved in antibody binding such as residues Gly549, Gly550,
Met591, Asn601, and Ala605. This probably reflects the confor-
mational change in hIL-16 induced by antibody binding and
discussed below (Fig. 5).
The c14.1Fab interaction surface on hIL-16 includes several
basic residues, such as Arg564 and Arg596, which gives the bind-
ing site on hIL-16 an overall positive charge. The complimen-
tary face of the antibody includes four acidic residues from the
CDR loops (Asp100, Asp103, and Asp109 from CDR-H3; and
Glu59 from CDR-L2). Of these, Asp100 and Glu59 form salt
FIGURE 2.Mapping of the c14.1Fabbinding site onhIL-16 byminimal shift NMRanalysis.A, histogram revealing the backbone amideminimal shifts seen
for thehIL-16uponcomplex formationwith c14.1Fab. The regionsof regular secondary structure are indicatedabove the plotbyblue bars for-helices andblue
arrows for -sheets. B,mapping of the minimal shift NMR data onto surface and ribbon representations of hIL-16, with significantly perturbed residues (shift

0.10 ppm) colored with a gradient from white to red. Residues for which no minimal shift data were obtained are also shown in white. Residue Trp600,
experiencing the greatest shift, is highlighted. C, a small region from the 15N-1H TROSY spectra of 15N-labeled hIL-16 both free (blue) and in complex (red) with
c14.1Fab, with the assignments for hIL-16 indicated. It is clear that the backbone amide peaks for Val534, Ile615, and Arg616 show reasonable shifts, whereas
Cys532 has substantially changed. Images were prepared using PyMol (The PyMOL Molecular Graphics System, version 1.7.4 Schrödinger, LLC.) and Topspin
(Bruker Biospin Ltd.).
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bridges with Arg596 and Arg564, respectively, as illustrated for
Asp100 and Arg596 in Fig. 4B, and which contributes to both the
specificity and stability of the complex formed. In total there
are 10 salt bridges and hydrogen bonds between hIL-16 and
c14.1Fab, together with 13 bridging water molecules, which
collectively form a complex hydrogen-bonding and ionic inter-
action lattice between the two proteins.
A major contributor to the specificity and affinity of the rec-
ognition of hIL-16 by the c14.1Fab is shape complementarily at
the center of the binding site, driven predominantly by residues
in CDR-H3 (Tyr101, Tyr102, and Asp103 (Fig. 4)). These CDR
residues occupy the GLGF cleft on hIL-16, which is a structural
feature typical of PDZ domains that commonly bind C-termi-
nal peptides (42). The previously reported solution structure of
free hIL-16 indicated that this cleft on the hIL-16 was too small
to accommodate peptide binding or other potential ligands and
was also occluded by the indole side chain of Trp600. In addi-
tion, there was no evidence of significantmobility of this region
in the free hIL-16 solution structures, nor have any peptides
been identified that bind to IL-16. Interestingly, the structure of
the c14.1FabhIL-16 complex reveals a significant antibody-in-
duced conformational change in the GLGF region of hIL-16,
which allows this cleft to accommodate residues fromCDR-H3.
The localized structural changes observed include a 2 Å shift of
the 2-strand to widen the binding site, and a 30o rotation
of the 1-helix to lever the Trp600 side chain from the blocked
recognition groove (Fig. 5). These antibody-induced conforma-
tional changes in bound hIL-16 permit the phenolic side chain
of Tyr102 fromCDR-H3 to occupy the remodeled hIL-16GLGF
cleft, formed by Phe545, Ser546, Leu547, Arg596, Ala599, Trp600,
and Ile603 (Fig. 4B). Furthermore, the acidic side chain of Asp103
from CDR-H3 is now able to form a hydrogen bond with the
amide backbone of Gly544 in a similar interaction to that seen
for peptides binding to the GLGF recognition motif of typical
PDZ domains (42). Although the interactions seen between
c14.1Fab and hIL-16 do not exactly mimic a typical peptide-
PDZ domain complex, the similarities suggest that IL-16 may
have the function to bind specific peptides or perhaps more
FIGURE 3. Structure of the c14.1FabhIL-16 complex.A, surface representa-
tion of hIL-16 (gray) bound to the c14.1Fab, showing the heavy (cyan) and 
(green) chains. B, ribbon representation of hIL-16 residues within 5 Å of
c14.1Fab heavy (cyan) and  (green) chains. There are 25 residues from hIL-16
that form a continuous contact surface and comprise of-strands2 and3,
the 2/3 loop, and 1 helix.
FIGURE 4. Summary of the molecular interactions between hIL-16 and
c14.1Fab. A, surface representation of hIL-16 (gray) and stick representation
of CDR loops from c14.1Fab from the heavy (cyan) and  (green) chains. The
interacting CDR loops follow the PDZ groove between the 1-helix and
2-strand. The c14.1Fab epitope revealed is distant to the putative CD4 bind-
ing site. B, stick representation of CDR-H3 from c14.1Fab interacting with the
putative functional paratope of hIL-16, including the PDZ pocket and the
GLGF cleft region. Tyr102 from CDR-H3 fits into the IL-16 PDZ pocket, formed
by residues Phe545, Ser546, Leu547, Arg596, Ala599, Trp600, and Ile603. The acidic
side chain of Asp103 from CDR-H3 forms a hydrogen bond with the amide
backbone of Gly544, in a similar manner to the carboxyl terminus of a typical
peptide binding to the GLGF recognition motif of a PDZ domain.
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likely is that a more substantial interface formed with a protein
partner could include a peptide moiety binding within this site
as part of a larger contact surface area. Indeed, a conformational
change of a PDZ domain to accommodate an interaction part-
ner has been observed previously in the Crb17 peptide binding
to the Pals1 PDZ domain (43). In this instance, Phe318 (occupy-
ing the same position as Trp600 in hIL-16) sterically blocks the
PDZ-binding groove in the ligand-free structure, but adopts a
different rotomer conformation away from the groove to
accommodate the Crb17 peptide. Furthermore, the phenyl side
chain of Phe318 packs against residuesArg1404 and Leu1405 from
Crb17, forming one side of the pocket into which the peptide
binds.
Potential Importance of Trp600 in Target Recognition—To
further probe the importance of the Trp600 side chain in regu-
lating the binding of target protein/peptides to the GLGF
region of hIL-16 we produced a W600A variant of hIL-16 and
determined the effects on c14.1 antibody binding using an
ELISA-based assay. The hIL-16 W600A mutation resulted in a
substantial change in the affinity of the interaction between the
c14.1 antibody and hIL-16. Removing the blocking tryptophan
side chain by substituting the residue with alanine might be
expected to increase the affinity of the c14.1 antibody to hIL-16.
However, the affinity was observed to decrease by 10-fold,
from an EC50 of 115 nM for native hIL-16 (supplemental Fig.
S1). This suggests that the energetic penalty arising from the
conformational change induced in hIL-16 on antibody binding
ismore than offset by the network of Van deWaals interactions
between the c14.1Fab CDR-H3 loop residues and the hydro-
phobic pocket formed by hIL-16 residues Phe545, Leu547,
Arg596, Ile603, and,most importantly, the indole side chain from
Trp600 (Fig. 4B).
Impact of the c14.1Fab on IL-16 Signaling—The location of
the CD4 binding site on hIL-16 was previously probed by
assessing the inhibition of IL-16-mediated chemotaxis by linear
peptides derived from IL-16, which suggested a role for the
616RRKS619motif (19). This putativeCD4binding site is located
on the opposite face of hIL-16 to the c14.1Fab binding site
reported here. This raises intriguing questions regarding the
mechanistic basis of the inhibitory activity of the 14.1 antibody.
Minimal shift NMR experiments were used to assess the
binding of CD4 domains D1–D4 andCD4D3D4 to 15N-labeled
hIL-16 and to establish if CD4 binding was affected by c14.1Fab
binding. Surprisingly, in samples with a 5:1 molar excess of
either CD4 D1–D4 or D3D4 we observed no shifts in the back-
bone amide signals of hIL-16, indicating no significant interac-
tion between the two proteins under the experimental condi-
tions used (supplemental Fig. S2). In agreement with the
previously publishedNMR structural studies of hIL-16, the line
widths of the backbone amide NMR signals observed are con-
sistent with a predominantly monomeric hIL-16. Interestingly,
some reports suggest that CD4 only binds to multimeric forms
of hIL-16 (44), however, the inhibitory c14.1Fab clearly binds to
monomeric hIL-16 with high affinity.
Attempts to directly or indirectly observe hIL-16 binding to
cell lines expressing CD4 by flow cytometry also detected no
interaction between CD4 and hIL-16 (supplemental Fig. S3).
Fluorescence-activated cell sorting (FACS) experiments
showed that recombinant hIL-16 was unable to compete off
bound anti-CD4 antibody OKT4, despite concentrations of
hIL-16 up to 100 mg/ml. Previous studies have suggested that
IL-16 dimerization or tetramerizationmay be a requirement for
CD4 binding and chemoattractant activity, which could
account for the lack of CD4 binding observed here, however, it
is unclear as to whymammalian expressed IL-16would bemul-
timeric. The purified mature hIL-16 expressed in E. coli and
used for the work reported here shows no tendency to form
multimeric species at concentrations over 1 mM, which may
suggest that the multimeric forms of hIL-16 reported in mam-
malian cell extracts may involve other protein partners. How-
ever, the inhibitory c14.1Fab clearly binds with high affinity to
the E. coli expressed hIL-16 monomer and neither sterically
blocks or perturbs the proposed CD4-binding site on hIL-16.
Structure-basedDesign of SmallMolecules toTarget the IL-16
Functional Site Recognized by c14.1Fab—The innovative use of
antibodies and antibody fragments to identify opportunities for
small molecule drug development on a range of proteins
selected as attractive therapeutic targets has been proposed
recently (45). This includes the identification of antibodies that
modulate target protein activity by binding to regulatory sites,
with structures obtained for these antibody-target protein
complexes used to inform and guide the development of small
molecule inhibitors or activators as potential drugs. The struc-
tural studies of the c14.1FabhIL-16 complex reported here rep-
resent an excellent example of the potential of antibody-as-
sisted approaches, with the conformational changes induced by
antibody binding revealing new opportunities for small mole-
cule modulation of IL-16 activity. This method of probing the
surface of target proteins, using antibodies as tools, to find
allosteric and functional pockets is an innovative and exciting
prospect and has the potential to revolutionize drug discovery
for a wide range of protein targets.
FIGURE 5. Induced conformational changes to hIL-16 following c14.1Fab
binding. Stick and schematic representation of hIL-16 before (orange) and
after (gray) c14.1Fab binding. The interaction between hIL-16 and c14.1Fab
results in a 30 degree rotation of the 1-helix, displacing Trp600 from the
blocked PDZ recognition groove and opening a pocket for Tyr102 from
CDR-H3 to bind. The 1-helix rotation also leads to a conformational change
to Phe597, forming a hydrophobic groove for Tyr101 from CDR-H3 to pack
against. These conformational shifts in hIL-16 result in the formation of a
typical PDZ pocket to permit protein-protein interactions, suggesting that
this conformational change may be associated with the biological activity of
hIL-16.
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SUPPLEMENTARY FIGURE 1.  c14.1 antibody binding to plate-bound hIL-16 constructs using 
an ELISA-type binding assay. Microtiter wells were coated with either hIL-16 (closed blue circles) or 
hIL-16 W600A (closed green squares) at various concentrations to determine their binding specificity for 
c14.1 antibody. The c14.1 antibody was detected using a secondary anti-Fc antibody conjugated to HRP 
(1:5000) and then developed.  Data were analyzed by GraphPad Prism software.  The ELISA binding 
study showed that mutating residue Trp600 to alanine in hIL-16 resulted in a ~10-fold increase in the 
EC50 value from 115.1 nM to >858.7 nM, demonstrating the importance of Trp600 in the interaction 
interface.  
 
SUPPLEMENTARY FIGURE 2.  Absence of a measurable direct interaction between hIL-16 and 
CD4 by NMR.  Shown are overlaid 15N-1H HSQC spectra of 15N-labelled hIL-16 both in the absence 
(blue) and presence (red) of recombinant unlabelled hCD4 domains D1-D4.  The spectra overlay very 
closely, showing no discernable shifts in the spectra of 15N-labelled hIL-16 in the presence of 5-molar 
excess of CD4, suggesting no interaction between hIL-16 and CD4. 
 
SUPPLEMENTARY FIGURE 3.  Lack of detectable binding of IL-16 to cell surface CD4.  (A) CD4 
+ve Jurkat cells were stained with a dose response curve of Biotinylated IL-16 (33mg/mL, 3.3mg/mL, 
300ng/mL, 33ng/mL, 3.3ng/mL) or Biotinylated OKT4 antibody, (500ng/mL) and subsequently detected 
with Streptavidin AlexaFluor 488. Red histograms OKT4 antibody staining, blue histograms biotinylated 
IL-16, green Streptavidin AlexaFluor 488 only. (B) Displacement of OKT4 from CD4+ve SupT1 cells. 
Red histograms OKT4 antibody staining, (500ng/mL), blue histograms hIL-16 dose response curve at 
100mg/mL, 25mg/mL, 10mg/mL, 2.5mg/mL, 1mg/mL, green Streptavidin AlexaFluor 488 only.  The 
FACS data indicate no direct binding of hIL-16 to CD4. 
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